A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

ClinicalTrials.gov

This study is not yet open for participant recruitment. 

 

Verified May 2013 by Array BioPharma

Sponsor:

Array BioPharma

Information provided by (Responsible Party):

Array BioPharma

ClinicalTrials.gov Identifier:

NCT01849874

First received: May 6, 2013

Last updated: May 7, 2013

Last verified: May 2013 

 

  Purpose

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Approximately 300 patients from North America, Europe and Asia Pacific will be enrolled in this study.